Are Seniors Being Used as CBD Guinea Pigs in Medicare Research?
Seniors CBD clinical research is gaining attention due to Medicare-funded studies involving elderly patients. Concerns arise about safety protocols and clinical oversight in these programs. Proper research design is crucial to protect seniors in CBD…
FloraWorks Announces TruCBN(TM) Readiness for CMS Substance Access Program
The CBN cannabinoid safety profile is advancing with FloraWorks' TruCBN readiness for CMS Substance Access. Clinical trial data show adverse events comparable to placebo, supporting safety. This progress may improve patient access to regulated…
CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited
Medicare CBD coverage limitations define the scope of this new federally-funded healthcare pilot. The program marks a cautious step toward integrating cannabis therapeutics with strict eligibility criteria. Coverage remains limited, reflecting early…
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule | Insights | Holland & Knight
CMS has finalized the Medicare Advantage payment rate increase for 2027, a key update affecting healthcare access for over 65 million Americans. This change influences reimbursement policies and patient care options, including those related to cannabis…
CMS Launches Medicare Pilot for Hemp and CBD Products
CMS has introduced a Medicare pilot hemp CBD coverage program to provide insurance for cannabis-derived products. This pilot aims to expand patient access while setting clinical standards. Clinicians should monitor the evolving Medicare hemp CBD program…